| AID1238192 | Nitric oxide release in phosphate-buffered-saline containing L-cysteine using 2,3-diaminonaphthlene at 50 uM after 90 mins by fluorescence assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
| Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors. |
| AID47937 | Inhibitory activity against human isoenzyme Carbonic anhydrase II | 2000 | Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
| Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. |
| AID1562203 | Drug metabolism in human plasma assessed as free nitrite level at 50 uM measured after 90 mins by 2,3-diaminonaphthalene-based fluorescence assay | 2019 | Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
| Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index. |
| AID52344 | Inhibitory activity against Clostridium histolyticum collagenase (ChC) was determined | 2000 | Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
| Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. |
| AID34026 | In vitro inhibition against yeast Alcohol dehydrogenase | 1995 | Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
| Prodrugs of nitroxyl as potential aldehyde dehydrogenase inhibitors vis-a-vis vascular smooth muscle relaxants. |
| AID108170 | Inhibitory activity against Matrix metalloprotease-9 | 2000 | Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
| Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. |
| AID1238190 | Nitric oxide release in phosphate-buffered-saline containing K3[Fe(CN)6] using 2,3-diaminonaphthlene at 50 uM after 90 mins by fluorescence assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
| Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors. |
| AID1562201 | Drug metabolism in pH 7.5 PBS assessed as nitric oxide release at 50 uM measured after 90 mins in presence of nitrite by 2,3-diaminonaphthalene-based fluorescence assay | 2019 | Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
| Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index. |
| AID1238186 | Nitric oxide release in phosphate-buffered-saline using 2,3-diaminonaphthlene at 50 uM after 90 mins by fluorescence assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
| Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors. |
| AID1238188 | Nitric oxide release in human plasma using 2,3-diaminonaphthlene at 50 uM after 90 mins by fluorescence assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
| Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors. |
| AID1562208 | Drug metabolism in pH 7.5 PBS assessed as S-nitroso-thiol level at 50 uM measured after 90 mins in presence of L-cysteine by 2,3-diaminonaphthalene-based fluorescence assay | 2019 | Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
| Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index. |
| AID1562205 | Drug metabolism in human plasma assessed as S-nitroso-thiol level at 50 uM measured after 90 mins by 2,3-diaminonaphthalene-based fluorescence assay | 2019 | Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
| Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index. |
| AID1238187 | Nitric oxide release in phosphate-buffered-saline using 2,3-diaminonaphthlene at 50 uM after 90 mins by Griess assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
| Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors. |
| AID50372 | Inhibitory activity against human isoenzyme Carbonic anhydrase I | 2000 | Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
| Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. |
| AID167559 | In vitro relaxation of precontracted rabbit aortic rings. | 1995 | Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
| Prodrugs of nitroxyl as potential aldehyde dehydrogenase inhibitors vis-a-vis vascular smooth muscle relaxants. |
| AID1562202 | Drug metabolism in pH 7.5 PBS assessed as nitric oxide release at 50 uM measured after 90 mins in presence of K3[Fe(CN)6] by 2,3-diaminonaphthalene-based fluorescence assay | 2019 | Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
| Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index. |
| AID107977 | Inhibitory activity against Matrix metalloprotease-8 | 2000 | Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
| Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. |
| AID1562204 | Drug metabolism in human plasma assessed as nitric oxide release at 50 uM measured after 90 mins by 2,3-diaminonaphthalene-based fluorescence assay | 2019 | Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
| Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index. |
| AID1238189 | Nitric oxide release in rat serum using 2,3-diaminonaphthlene at 50 uM after 90 mins by Griess assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
| Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors. |
| AID1562207 | Drug metabolism in pH 7.5 PBS assessed as nitric oxide release at 50 uM measured after 90 mins in presence of L-cysteine by 2,3-diaminonaphthalene-based fluorescence assay | 2019 | Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
| Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index. |
| AID1238191 | Nitric oxide release in phosphate-buffered-saline containing K3[Fe(CN)6] using 2,3-diaminonaphthlene at 50 uM after 90 mins by Griess assay | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
| Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors. |
| AID1562206 | Drug metabolism in pH 7.5 PBS assessed as free nitrite level at 50 uM measured after 90 mins in presence of L-cysteine by 2,3-diaminonaphthalene-based fluorescence assay | 2019 | Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
| Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index. |
| AID48278 | Inhibitory activity against bCA -IV | 2000 | Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
| Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. |
| AID108925 | Inhibitory activity against matrix metalloprotease-1 | 2000 | Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
| Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. |
| AID107189 | Inhibitory activity against Matrix metalloprotease-2 | 2000 | Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
| Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. |
| AID1796665 | Carbonic Anhydrase Enzyme Inhibition Assay from Article 10.1021/jm000027t: \\Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, a | 2000 | Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
| Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. |
| AID977610 | Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB | 2000 | Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
| Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |